MUC1 and non-small cell lung carcinoma: Indeed, four Muc1-based Phase III trials exploring cancer treatment have been completed, one of which used a Muc1 tandem repeat peptide as an immunogen (L-BLP25) in patients with stage III unresectable NSCLC after chemoradiation [260].